GSK Blasts Appeal Bid In Pa. Paxil Venue Dispute

Law360, New York (January 8, 2014, 8:12 PM EST) -- GlaxoSmithKline LLC on Monday blasted a bid to have the Third Circuit decide whether the company could send a suit alleging antidepressant drug Paxil caused birth defects from state to federal court more than a year after the suit began.

GSK challenged the plaintiffs' Dec. 23 petition for permission to appeal the company's removal of the case to federal court following a landmark Third Circuit ruling in June keeping a separate suit over GSK’s morning-sickness drug thalidomide in federal court, saying there were no exceptional circumstances...
To view the full article, register now.